Pfizer Inc. PFEhas announced initiation of dosing in a phase Ib study, evaluating its mini-dystrophin gene therapy candidate, PF-06939926, for the treatment of boys aged from five to 12 years with duchenne muscular dystrophy (DMD). Notably, DMD is a genetic disease characterized by muscle degeneration and weakness.
The company anticipates initial data from the study in the first half of 2019.Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться